We look forward to your post on the topic For all of you interested: watch out for news of TOLEBRUTINIB and FENEBRUTINIB, for us progressive MSers, in the upcoming Euopean Congress of MS in Copenhagen, Denmark (ECTRIMS). Currently in phase III (the last before filing to EMA or FDA), the drugs could tackle progression and “inactive” disease. Frequent in PPMS.